Abstract
We read with interest, the results of the faSScinate trial1 suggesting tocilizumab had a good safety profile in the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). SSc-ILD is, however,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have